000845466 000__ 04626cam\a2200541Ii\4500
000845466 001__ 845466
000845466 005__ 20230306144851.0
000845466 006__ m\\\\\o\\d\\\\\\\\
000845466 007__ cr\cn\nnnunnun
000845466 008__ 180806s2018\\\\gw\\\\\\ob\\\\000\0\eng\d
000845466 019__ $$a1048116725
000845466 020__ $$a9783319914428$$q(electronic book)
000845466 020__ $$a3319914421$$q(electronic book)
000845466 020__ $$z9783319914411
000845466 020__ $$z3319914413
000845466 035__ $$aSP(OCoLC)on1047729251
000845466 035__ $$aSP(OCoLC)1047729251$$z(OCoLC)1048116725
000845466 040__ $$aN$T$$beng$$erda$$epn$$cN$T$$dN$T$$dGW5XE$$dEBLCP$$dOCLCO$$dYDX$$dUAB
000845466 049__ $$aISEA
000845466 050_4 $$aRC268.4
000845466 08204 $$a616.994061$$223
000845466 24500 $$aSmall molecules in oncology /$$cUwe M. Martens, editor.
000845466 250__ $$aThird edition.
000845466 264_1 $$aHeidelberg :$$bSpringer,$$c[2018]
000845466 264_4 $$c©2018
000845466 300__ $$a1 online resource.
000845466 336__ $$atext$$btxt$$2rdacontent
000845466 337__ $$acomputer$$bc$$2rdamedia
000845466 338__ $$aonline resource$$bcr$$2rdacarrier
000845466 4901_ $$aRecent results in cancer research ;$$vvolume 211
000845466 504__ $$aIncludes bibliographical references.
000845466 5050_ $$aIntro; Preface; Contents; 1 Erlotinib; Abstract; 1 Introduction; 2 Mechanism of Action; 3 Non-small Cell Lung Cancer; 4 Pancreatic Adenocarcinoma; 5 Hepatocellular Carcinoma; 6 Other Tumour Entities; References; 2 Lapatinib; Abstract; 1 Introduction; 1.1 The Epidermal Growth Factor Receptor Family of Tyrosine Kinases; 1.2 Human Epidermal Growth Factor Receptors and Their Inhibition in Cancer; 2 Structure and Mechanism of Action; 3 Clinical Application; 3.1 Pharmacology; 4 Results from Clinical Trials; 4.1 Efficacy in Breast Cancer
000845466 5058_ $$a4.1.1 Second-Line Treatment and Beyond in Advanced Breast Cancer4.1.2 First-Line Treatment in Advanced Breast Cancer; 4.1.3 Neoadjuvant Treatment in Early Breast Cancer; 4.1.4 Adjuvant Treatment in Early Breast Cancer; 4.2 Efficacy in Gastrointestinal Cancer; 4.3 Tolerability; 5 Biomarkers; 6 Conclusion and Future Perspectives; References; 3 Regorafenib; Abstract; 1 Structure, Mechanism of Action, and Pharmacokinetics; 1.1 Mechanism of Action; 1.2 Pharmacokinetics and Elimination; 1.3 Regorafenib in Renal or Hepatic Impairment; 2 Preclinical Data; 3 Clinical Data
000845466 5058_ $$a3.1 Regorafenib in Metastatic Colorectal Cancer (mCRC)3.2 Regorafenib in Metastatic Gastrointestinal Stromal Tumors (mGIST); 3.3 Regorafenib in Hepatocellular Carcinoma (HCC); 3.4 Regorafenib in Metastatic Renal Cell Carcinoma (RCC); 3.5 Regorafenib in Soft-Tissue Sarcoma (STS); 4 Detailed Analysis of Toxicity; 4.1 Dermatological Toxicity; 4.2 Hypertension, Cardiac Ischemia, and Infarction; 4.3 Hepatotoxicity; 4.4 Gastrointestinal Perforation or Fistula; 4.5 Hemorrhage; 4.6 Embryo-Fetal Toxicity; 5 Drug Interactions; 5.1 Effect of Strong CYP3A4 Inducers; 5.2 Effect of Strong CYP3A4 Inhibitors
000845466 5058_ $$a5.3 Effect of Regorafenib on UGT1A1 Substrates6 Biomarkers; 7 Summary and Perspectives; References; 4 Crizotinib; Abstract; 1 Structure and Mechanism of Action; 2 Preclinical Data; 3 Clinical Data; 3.1 NSCLC; 3.2 Other Entities; 4 Toxicity; 5 Drug Interactions; 6 Biomarkers; 7 Summary and Perspectives; References; 5 Cabozantinib: Multi-kinase Inhibitor of MET, AXL, RET, and VEGFR2; Abstract; 1 Introduction; 2 Preclinical Properties and Pharmacokinetics; 3 Clinical Trials; 3.1 Phase I; 3.2 Phase III EXAM Trial; 3.3 Phase III Trials in Renal Cell Cancer (METEOR and CABOSUN)
000845466 5058_ $$a4 Cabozantinib Combination with Immuno-oncology5 Discussion; References; 6 Vemurafenib; Abstract; 1 Introduction; 2 Structure and Mechanism of Action; 3 Preclinical Data; 3.1 Pharmacokinetics and Drug Interactions; 3.2 Vemurafenib in Melanoma; 3.3 Toxicity; 3.4 Vemurafenib in Colorectal Cancer; 4 Vemurafenib in Papillary Thyroid Cancer; 4.1 Vemurafenib in Non-small-Cell Lung Cancer (NSCLC); 4.2 Vemurafenib in Hairy Cell Leukaemia; 4.3 Vemurafenib in Other Cancers; 4.4 Biomarkers and Monitoring of Vemurafenib Treatment; 5 Summary and Perspectives; References; 7 Trametinib (GSK1120212)
000845466 506__ $$aAccess limited to authorized users.
000845466 588__ $$aDescription based on print version record.
000845466 650_0 $$aCancer$$xMolecular aspects.
000845466 650_0 $$aAntineoplastic agents.
000845466 650_0 $$aCancer$$xTreatment.
000845466 7001_ $$aMartens, Uwe M.,$$eeditor.
000845466 77608 $$iPrint version: $$z3319914413$$z9783319914411$$w(OCoLC)1031315959
000845466 830_0 $$aRecent results in cancer research ;$$vv. 211.
000845466 852__ $$bebk
000845466 85640 $$3SpringerLink$$uhttps://univsouthin.idm.oclc.org/login?url=http://link.springer.com/10.1007/978-3-319-91442-8$$zOnline Access$$91397441.1
000845466 909CO $$ooai:library.usi.edu:845466$$pGLOBAL_SET
000845466 980__ $$aEBOOK
000845466 980__ $$aBIB
000845466 982__ $$aEbook
000845466 983__ $$aOnline
000845466 994__ $$a92$$bISE